Physician profile
James O Browne
NPI 1447417514
$4,761,143.50
in general payments reported to CMS, 2019-2025
10 companies · $1.0M in 2025
The $1.0M reported for 2025 was more than what 99% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457K · 2020: $493K · 2021: $652K · 2022: $869K · 2023: $1.0M · 2024: $218K · 2025: $1.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.8M · Consulting Fee: $444K · Travel and Lodging: $46K · Food and Beverage: $3,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,796,301.69 |
| Consulting Fee | $444,205.19 |
| Travel and Lodging | $46,341.54 |
| Food and Beverage | $3,246.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $4,686,189.44 | 2019-2025 | Djo Surgical |
| Osteoremedies, LLC | $62,657.85 | 2019-2025 | Biobrush, Remedy Spacer, Biowash Surgical Irrigation |
| Insight Medical Systems, INC. | $7,714.93 | 2023-2024 | Arvis |
| Heron Therapeutics, INC. | $2,184.47 | 2019-2025 | Zynrelef |
| Kci USA, INC. | $961.98 | 2023 | Ioban 2, 3m Ioban |
| Kinamed, INC. | $875.00 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $273.11 | 2023 | Iovera, Exparel, Zilretta |
| Djo, LLC | $216.49 | 2019 | |
| Pacira Therapeutics, INC. | $50.00 | 2019 | |
| Depuy Synthes Sales INC. | $20.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.